


Ask a doctor about a prescription for IRBESARTAN/HYDROCHLOROTHIAZIDE TECNIGEN 300 mg/25 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Irbesartan/Hydrochlorothiazide TecniGen 300 mg/25 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Irbesartan/Hydrochlorothiazide TecniGen is a combination of two active substances, irbesartan and hydrochlorothiazide.
Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels, causing them to constrict. This results in an increase in blood pressure.
Irbesartan prevents angiotensin-II from binding to these receptors, relaxing blood vessels and reducing blood pressure.
Hydrochlorothiazide belongs to a group of medicines (called thiazide diuretics) that increase the amount of urine produced, reducing blood pressure. The two active substances in Irbesartan/Hydrochlorothiazide TecniGen work together to achieve a reduction in blood pressure that is greater than that achieved with either substance alone.
Irbesartan/Hydrochlorothiazide TecniGen is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone does not provide adequate control of blood pressure.
Do not take Irbesartan/Hydrochlorothiazide TecniGen
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Irbesartan/Hydrochlorothiazide TecniGen
Tell your doctorin any of the following cases:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking irbesartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking irbesartan/hydrochlorothiazide on your own.
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Irbesartan/Hydrochlorothiazide TecniGen”
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. Irbesartan/Hydrochlorothiazide TecniGen is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy as it may cause serious harm to your baby.
You must also inform your doctor:
Athletes:
This medicine contains hydrochlorothiazide, which may produce a positive result in doping tests.
Children and adolescents
Irbesartan/Hydrochlorothiazide TecniGen should not be given to children and adolescents (under 18 years of age).
Use of other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Diuretics, such as hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide TecniGen, may interact with other medicines. Do not take preparations containing lithium with Irbesartan/Hydrochlorothiazide TecniGen without your doctor's supervision.
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Irbesartan/Hydrochlorothiazide TecniGen” and “Warnings and precautions”)
You may need to have blood tests if you take:
It is also important to inform your doctor if you are taking:
Taking Irbesartan/Hydrochlorothiazide TecniGen with food, drinks, and alcohol
Irbesartan/Hydrochlorothiazide TecniGen can be taken with or without food.
Due to the hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide TecniGen, if you drink alcohol while taking this medicine, you may experience increased dizziness when standing up, especially when getting up from a sitting position.
Pregnancy, breastfeeding, and fertility
If you are pregnant, breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking Irbesartan/Hydrochlorothiazide TecniGen before you become pregnant or as soon as you find out you are pregnant and will recommend that you take a different blood pressure-lowering medicine instead. Irbesartan/Hydrochlorothiazide TecniGen is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding, as Irbesartan/Hydrochlorothiazide TecniGen is not recommended for use during breastfeeding. Your doctor may decide to prescribe a treatment that is more suitable if you wish to breastfeed, especially if you are breastfeeding newborns or premature babies.
Driving and using machines
No studies have been performed on the ability to drive and use machines. It is unlikely that Irbesartan/Hydrochlorothiazide TecniGen will affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, talk to your doctor before driving or using machines.
Irbesartan/Hydrochlorothiazide TecniGen contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.
Follow exactly the instructions of your doctor or pharmacist for taking this medicine. If you are unsure, consult your doctor or pharmacist again.
Dose
The recommended dose of Irbesartan/Hydrochlorothiazide TecniGen is one or two tablets per day. In general, your doctor will prescribe Irbesartan/Hydrochlorothiazide TecniGen when previous treatments have not sufficiently reduced your blood pressure. Your doctor will advise you on how to switch from previous treatments to Irbesartan/Hydrochlorothiazide TecniGen.
Method of administration
Irbesartan/Hydrochlorothiazide TecniGen is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). You can take Irbesartan/Hydrochlorothiazide TecniGen with or without food. Try to take your daily dose at the same time each day. It is important that you continue to take Irbesartan/Hydrochlorothiazide TecniGen until your doctor advises you to stop.
The maximum blood pressure-lowering effect should be achieved within 6-8 weeks after starting treatment.
The score line is only to facilitate breaking the tablet if you have difficulty swallowing it whole.
If you take more Irbesartan/Hydrochlorothiazide TecniGen than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
Children should not take Irbesartan/Hydrochlorothiazide TecniGen
Irbesartan/Hydrochlorothiazide TecniGen should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.
If you forget to take Irbesartan/Hydrochlorothiazide TecniGen
If you accidentally miss a dose, simply take your normal dose when it is due next. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. Some of these effects can be serious and may require medical attention.
Rarely, cases of allergic skin reactions (skin rash, hives) have been reported in patients treated with irbesartan, as well as localized inflammation in the face, lips, and/or tongue.
If you experience any of the above symptoms or have difficulty breathing, stop taking Irbesartan/Hydrochlorothiazide TecniGen and contact your doctor immediately.
The frequency of adverse effects listed below is defined using the following convention:
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Adverse effects reported in clinical studies for patients treated with Irbesartan/Hydrochlorothiazide TecniGen were:
Common Adverse Effects(may affect up to 1 in 10 people):
If any of these adverse effects cause you problems, consult your doctor.
Uncommon Adverse Effects(may affect up to 1 in 100 people)
If any of these adverse effects cause you problems, consult your doctor.
Adverse Effects Since the Marketing of Irbesartan/Hydrochlorothiazide TecniGen
Since the marketing of Irbesartan/Hydrochlorothiazide TecniGen, some adverse effects have been reported. Adverse effects with unknown frequency are: headache, ringing in the ears, cough, taste alteration, indigestion, joint and muscle pain, liver function disorders, and kidney failure, high potassium levels in the blood, and allergic reactions such as skin rash, hives, swelling of the face, lips, mouth, tongue, or throat. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been observed.
As with all combinations of two active ingredients, adverse effects associated with each component cannot be ruled out.
Adverse Effects Associated Only with Irbesartan
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea (rare).
In addition to the adverse effects described above, chest pain and reduced platelet count (unknown frequency) have also been observed.
Adverse Effects Associated with Hydrochlorothiazide in Monotherapy:
Lack of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); pancreatitis characterized by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can lead to frequent infections, fever; reduced platelet count (cells essential for blood clotting), reduced red blood cell count (anemia) characterized by fatigue, headaches, shortness of breath when exercising, dizziness, and paleness; kidney disease; pulmonary disorders including pneumonia or fluid accumulation in the lungs; increased skin sensitivity to the sun; blood vessel inflammation; a skin disease characterized by peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that can appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasms; heart rhythm alteration; reduced blood pressure after a change in body position; swelling of the salivary glands; high blood sugar levels; sugar in the urine; increased levels of certain blood fats; high uric acid levels in the blood, which can cause gout.
Very rare (may affect up to 1 in 10,000 people): Acute respiratory distress (signs include severe respiratory distress, fever, weakness, and confusion).
Frequency "unknown": Skin and lip cancer (non-melanoma skin cancer). Decreased vision or eye pain due to elevated pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma].
It is known that adverse effects associated with hydrochlorothiazide can increase with higher doses of hydrochlorothiazide.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines. Website: www.notificaram.es.
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the carton and on the blister pack after CAD.
The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and unused medicines in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist where to throw away unused medicines. This way, you will help protect the environment.
Composition of Irbesartan/Hydrochlorothiazide TecniGen
Appearance of the Product and Package Contents
The tablets of Irbesartan/Hydrochlorothiazide TecniGen 300 mg/25 mg are pink/dark pink, convex, and oblong.
Irbesartan/Hydrochlorothiazide TecniGen 300 mg/25 mg tablets are available in blister packs of 14, 28, or 56 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D. Edificio América. Polígono Arroyo de la Vega,
28108 Alcobendas (Madrid) SPAIN
Manufacturer
Atlantic Pharma – Produções Farmacêuticas, S.A.
Rua da Tapada Grande, n.º 2, Abrunheira, 2710-089 Sintra, Portugal
Date of the Last Revision of this Prospectus: February 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of IRBESARTAN/HYDROCHLOROTHIAZIDE TECNIGEN 300 mg/25 mg FILM-COATED TABLETS in October, 2025 is around 19.29 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IRBESARTAN/HYDROCHLOROTHIAZIDE TECNIGEN 300 mg/25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.